Welcome to ReverseAMD.com

Dr. Lundgren is not currently treating patients. He is deciding whether he will move into full-time retirement or not. Please send us your contact information if you would like to learn his final decision, which will be made in the next few months.

This site is dedicated to the treatment of Age-Related Macular Degeneration (AMD) based upon the work of Alston C. Lundgren, MD. Dr. Lundgren developed the experimental Santa Fe Eye Protocol to Reverse the Vision Loss of Macular Degeneration – henceforth abbreviated The Santa Fe Eye Protocol. It is the only documented treatment to reverse vision loss in cases of both Wet and Dry AMD.

Dr. Lundgren presented his November 2007 to August 2008 results at the 18th International Congress of Eye Research (English speaking academic ophthalmologists) in Beijing September 2008. A link to this paper is on the upper right of this page.

He presented his findings and his protocol to the University of Pittsburgh Medical Center Eye Center in May 2010 and the Annual Scientific Symposium of the American Academy of Medical Acupuncture in late April 2010. Links to these presentations are on the upper right of this page.

The Santa Fe Eye Protocol is a three-part treatment that achieves measurable results through minimally invasive techniques.

  1. Small steel studs are inserted in regions of the ear whose nerve endings have been shown to correspond with specific areas of the brain. By stimulating these nerves, cortisone and oxygen-rich blood are induced in the region of the retina.
  2. Needle electrodes are inserted in the fat around the eyeball and are stimulated with a mild electrical current. These electrodes stimulate the retina and surrounding tissues and probably increase blood flow to the retina.
  3. In Spring 2007, a 3rd component was added – electrically stimulating the scalp over the visual cortex which occupies a considerable portion of the brain.

In the course of over 10,000 individual eye treatments on more than 1,500 individual patients, and as reported in articles in peer-reviewed medical journals, this combination of physical and electric stimulation currently results in measurable improvements in the vision of approximately 85% of individual eyes and 93% of patients when both eyes are combined.

The Santa Fe Eye Protocol has few risks, is minimally invasive and therefore is a welcome addition to traditional treatments such as vitamin therapy, thermal laser, Photodynamic Therapy, and various brand-name anti-angiogenic medications.

Dr. Lundgren is so confident in the results of this protocol that all charges will be refunded if after four treatments there is not objective improvement in visual acuity. As measured on National Eye Institute ETDRS charts, one eye must test at least one line better in either near or distant vision. Most patients show much greater improvement.

Please also visit the AMD Overview page, but here’s a summary you might find helpful:

Age-Related Macular Degeneration (AMD – formerly ARMD) is a condition of the macula, part of the retina that is responsible for the central vision needed to read, write, and drive.

The retina is made of specialized cells called photoreceptors that convert light into electrical impulses that stimulate the brain. The macula, a 1/8 inch area near the center of the retina, is dense with cone-type photoreceptors, resulting in a density of electrical signals. These signals translate into the perception of focused, central vision, as well as color vision.

As people age and circulation to the retina decreases, the macula degenerates and the capacity for direct central vision is lost. The ability to see fine details is lost: patients see edges of images, but not what is in the middle. Eventually a blank or dark spot – called a scotoma – forms in the center of the visual field, colors become less vivid, blurriness and wavy lines may appear, and in some cases, the patient becomes legally blind (legally defined as having vision of 20/200 or less with best correction).

In Neovascular, or Wet Macular Degeneration, blood vessels in the retina become abnormal and prone to leaking. Leakage of the vessel may cause a sudden loss of vision, sometimes in a matter of days. Wet AMD is often treated with lasers or injections that stop or slow vascular growth. The Santa Fe Eye Protocol is the only documented treatment that can improve the vision of patients with Wet AMD, and without the use of lasers or injections.

Non-neovascular or Dry Macular Degeneration is more common than Wet AMD and affects 90% of patients. Dry AMD is characterized by a loss of pigment in the retina and small deposits of drusen – a waste product – in the layer of membrane behind the retina. Outside of the Santa Fe Eye Protocol, the only proven treatment for this condition is high doses of antioxidant vitamins plus various supplements you can read about on the AMD Overview page. Here are two good documents to review:

  • Richer, Stuart et al; Veterans Lutein Antioxidant Supplementation Trial (LAST); Optometry; April 2004; 75:216-30
  • Richer, Stuart et al; LAST II; Optometry; May 2007; 78 213-219
  • The Santa Fe Eye Protocol significantly improves vision even in those persons who already are supplementing and we encourage people to supplement if they are not already.

    Additional Macular Degeneration Treatment Information and Further Reading

    In Dr. Lundgren’s opinion, the best and most understandable explanation of the mechanism of AMD comes from the first part of the Caltech Alumni Magazine, “Engineering and Science”, No 3, 2006. Click here to access the pdf (2.1 MB).

    The October 5, 2006 issue of The New England Journal of Medicine, pages 1474-1485 published a Review Article titled “Age Related Macular Degeneration” by T. V. M. de Jong. Click here to read the abstract.

    With kind permission of Stuart Richer, OD, PhD, text of his articles may be accessed below.

    Double masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: the veterans LAST study (Lutein Antioxidant Supplementation Trial) click here to read the article.

    LAST II: Differential Temporal responses of macular pigment density in patients with atrophic age-related macular degeneration to dietary supplementation with xanthophylls. click here to read the article.

    Updated: 11 March 2014